Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 ...

This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: You can take Mounjaro at any time of day. The best ...

Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial ...

VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy ...

As of Wednesday, December 31, Xeris Biopharma Holdings, Inc.’s XERS share price has surged by 8.66%, which has investors questioning if this is right time to sell.

Millions of Australians are set to benefit from the price of medicine going down for the first time in over 20 years. From ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Millions of Australians are set to benefit from the price of medicine going down for the first time in over 20 years. From ...

Clinical setbacks, worse-than-expected financial results, and a loss of market share in its most important therapeutic area ...

Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research indicates for men evaluating prescription testosterone pathways heading into ...

KORU Medical Systems, Inc.KRMD recently announced that it has submitted a 510(k) premarket notification for FDA clearance to ...

A privately held biopharmaceutical company based in the United States. Its development and planned commercialization ...